Table 1: Clinical characteristic, treatment and outcome in STEMI.
VARIABLE |
TOTAL |
MALE |
FEMALE |
P VALUE |
|
N |
510 |
336 (65.8%) |
174 (34.2) |
<0.001 |
|
CLINICAL CHARACTERISTIC |
|||||
MEAN AGE |
55.8 yrs |
53.6 yrs |
58 yrs |
<.001 |
|
SMOKER |
235 (46.07) |
227 (67.5%) |
8 (4.5%) |
<0.001 |
|
HYPERTENSION |
210 (41.1%) |
122 (36.3%) |
88 (50.5%) |
<0.001 |
|
DIABETES |
174 (34.1%) |
91 (27.08%) |
83 (47.7%) |
<0.001 |
|
BMI>25 |
135 (26.4%) |
66 (19.6%) |
69 (39.6%) |
0.003 |
|
H/O OF PREVIOUS MI |
88 (17.25%) |
45 (13.3%) |
33 (18.91%) |
0.11 |
|
DYSLIPIDEMIA |
170 (33.3%) |
89 (26.4%) |
81 (46.5%) |
0.001 |
|
MEAN TIME TO
PRESENTATION |
9.98 hrs |
9.51 hrs |
10.46 hrs |
0.26 |
|
ATYPICAL PRESENTATION |
102 (20%) |
47 (13.98%) |
57 (31.6%) |
<0.001 |
|
TREATMENT IN HOSPITAL |
|||||
ASPIRIN |
506 (99.2%) |
334 (99.4%) |
172 (98.8%) |
0.6 |
|
CLOPIDOGREL |
502 (98.4%) |
332 (98.8%) |
170 (97.7%) |
0.45 |
|
STATINS |
506 (99.2%) |
334 (99.4%) |
172 (98.8%) |
0.6 |
|
ACEI/ARB |
459 (90.1%) |
301 (89.5%) |
158 (90.8%) |
0.75 |
|
Beta blockers |
456 (89.4%) |
300 (89.2%) |
156 (89.6%) |
1.00 |
|
LMWH |
496 (98.4%) |
327 (97.3%) |
169 (97.1%) |
1.00 |
|
Thrombolysis |
199 (39.1%) |
150 (44.34%) |
50 (28.73%) |
0.04 |
|
PCI |
75 (14.7%) |
59 (17.5%) |
16 (9.1%) |
0.01 |
|
OUTCOME AT 30 DAYS |
|||||
HEART FAILURE/ CARDIOGENIC SHOCK |
65 (12.7%) |
35 (10.41%) |
30 (17.2%) |
0.03 |
|
REINFARCTION |
34 (6.66%) |
18 (5.35%) |
16 (9.1%) |
0.13 |
|
CARDIAC ARREST
(resuscitated) |
33 (6.47%), |
17 (5.05%) |
16 (9.1%) |
0.08 |
|
STROKE |
3 (0.58%) |
3 (0.89%) |
0% |
0.55 |
|
DEATH |
60 (11.76%) |
33 (9.8%) |
27 (15.51%) |
0.06 |
|
Cause of death |
Pump failure |
27 (45%) |
14 (42.4%) |
13 (48.1%) |
0.14 |
Asystole |
10 (18.51%) |
6 (18.1%) |
4 (14.81%) |
0.74 |
|
VF |
10 (18.51%) |
6 (18.1%) |
4 (14.81%) |
0.74 |
|
Multifactorial |
13 (24%) |
7 (21.21%) |
06 (22.2%) |
0.38 |